Gerresheimer to present portfolio of containment solutions, drug delivery systems, digital solutions for therapy support at Pharmapack; company to focus on specialized primary packaging--such as COP injection vials, medication pumps--for sensitive drugs

Sample article from our Packaging Industry

January 11, 2024 (press release) –

  • Broad portfolio for biologics, including cell and gene therapy products 
  • Digitally connected Drug Delivery Devices for self-administration 

  • New performance levels for the right choice of product 

  • Sustainability by design from development to production 


Düsseldorf, January 10, 2024. Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industry will present its comprehensive portfolio of containment solutions, drug delivery systems and digital solutions in areas such as therapy support at this year’s Pharmapack. The company’s presence at the trade fair will focus on specialized primary packaging solutions for sensitive innovative drugs such as biopharmaceuticals, including cell and gene therapy products — from COP injection vials for cryogenic temperatures through to medication pumps. Thanks to its extensive portfolio and long-standing expertise, Gerresheimer delivers the right solution for every drug and every production requirement, including RTF solutions that minimize risks during the filling process, reduce overall costs and accelerate time to market. Alongside its own efforts to increase sustainability, Gerresheimer helps customers take this topic into account as early as during the product development stage through its EcoDesign approach. On top of that, the company provides sterilization and RTF packaging options that are more environmentally friendly. Gerresheimer will be presenting its solutions at Pharmapack Paris from January 24 - 25 in hall 7.2, booth F60 and in the Innovation Gallery. Gerresheimer experts will also share insights and expertise in innovation track presentations and learning lab sessions.  

"Highlights of our portfolio, which we will presenting at Pharmapack 2024, include our latest solutions that meet the highest requirements of complex drug formulations, therapies, and fill & finish processes”, says Dr. Lukas Burkhardt, member of the Gerresheimer Management Board 

Gerresheimer Conference Highlights at Innovation Track and Learning Lab 
Gerresheimer experts will share insights and expertise several innovation track presentations and learning lab sessions: 

Opportunities and Challenges in Connected Drug Delivery  
Date: 24th January 
Time: 11.30 - 11.40 h 
Venue: Conference Theatre, Room 721 
Speaker: Mithun Ratnakumar, Director Technology Strategy & Governance at Gerresheimer 

Challenges of subcutaneous drug delivery for self-administration 
Date: 24th January 
Time: 11.55 - 12.20 h 
Venue: Conference Theatre, Room 721 
Speaker: Oliver Haferbeck, Global Senior Vice President Innovation Advanced Technologies at Gerresheimer 

Gerresheimer performance levels for the right choice of product platform 
Date: 24th January 
Time: 15.50 - 16.20 h 
Venue: Learning Lab Theatre, L20 
Speakers: Stefan Verheyden, Global Vice President Biological Solutions and Syringes, and Holger Krenz, Global Vice President Business Development High Value Products Tubular Glass at Gerresheimer 

Joint Session with Sterigenics – new option for sterilizing prefilled ophthalmic syringes 
Date: 25th January 
Time: 10:10 - 10:40 
Venue: Learning Lab Theatre, L20 
Speakers: Bernd Zeiss, Head of Scientific Affairs and Application Technologies at Gerresheimer, and Eric Offermann, Principal Scientist R&D Sterigenics 

Gerresheimer at Pharmapack Paris 
Gerresheimer presents its portfolio at Pharmapack, Paris Expo, Porte de Versailles, from January 24-25, 2024, in Hall 7.2 at booth F60.  

Interested trade visitors can schedule an appointment with one of the Gerresheimer experts at


About Gerresheimer   
Gerresheimer is an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems and medical devices as well as solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. With 36 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. With over 11,000 employees, the company generated revenues of around €1.82bn in 2022. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). 

Contact Gerresheimer AG  
Jutta Lorberg  
Head of Corporate Communication  
P +49 211 6181 264 

Marion Stolzenwald 
Senior Manager Corporate Communication 
P +49 1722424185 

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order packaging industry coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.